[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100581897":3},{"organization":4,"outcomesModule":7,"designInfo":14,"detailedDescription":13,"studyPopulation":13,"armGroups":20,"interventions":26,"overallOfficials":13,"centralContacts":32,"locations":38,"responsibleParty":51,"collaborators":13,"id":53,"slug":13,"hasResults":54,"nctId":55,"briefTitle":56,"officialTitle":57,"acronym":13,"eligibilityCriteria":58,"healthyVolunteers":54,"sex":59,"minAge":60,"maxAge":61,"enrollmentInfo":62,"targetDuration":13,"studyType":65,"phases":66,"briefSummary":69,"conditions":70,"keywords":13,"overallStatus":72,"whyStopped":13,"lastUpdateSubmitDate":73,"lastUpdatePostDateStruct":74,"startDateStruct":77,"completionDateStruct":79,"leadSponsor":81,"locationsCount":82},{"fullName":5,"class":6},"Zhejiang Provincial People's Hospital","OTHER",{"primaryOutcomes":8,"secondaryOutcomes":13,"otherOutcomes":13},[9],{"measure":10,"description":11,"timeFrame":12},"Safety and tolerability","Safety and tolerability at 28 days after combination therapy, dose limiting toxicity (DLT) and maximum tolerated dose (MTD) were determined.","From the start of the trial to day 56 after the first infusion of CAR-NK.",null,{"allocation":15,"interventionModel":16,"interventionModelDescription":13,"primaryPurpose":17,"observationalModel":13,"timePerspective":13,"maskingInfo":18},"NA","SINGLE_GROUP","TREATMENT",{"masking":19,"maskingDescription":13,"whoMasked":13},"NONE",[21],{"label":22,"type":23,"description":13,"interventionNames":24},"treated with CAR-NK immune cells combined with PD-1 monoclonal antibody.","EXPERIMENTAL",[25],"Drug: NKG2D CAR-NK with PD-1 Antibody",[27],{"type":28,"name":29,"description":30,"armGroupLabels":31,"otherNames":13},"DRUG","NKG2D CAR-NK with PD-1 Antibody","Treated with CAR-NK immune cells combined with PD-1 monoclonal antibody.",[22],[33],{"name":34,"role":35,"phone":36,"phoneExt":13,"email":37},"Minghua Ge","CONTACT","+86-0571 87666666","geminghua@hmc.edu.cn",[39],{"facility":5,"status":13,"city":40,"state":41,"zip":42,"country":43,"countryCode":44,"cosmosGeoPoint":45,"geoPoint":50,"contacts":13},"Hangzhou","Zhejiang","310014","China","CN",{"type":46,"coordinates":47},"Point",[48,49],120.16142,30.29365,{"lat":49,"lon":48},{"type":52,"investigatorFullName":13,"investigatorTitle":13,"investigatorAffiliation":13,"oldNameTitle":13,"oldOrganization":13},"SPONSOR","100581897",false,"NCT06856278","Clinical Study of NKG2D CAR-NK Combined with PD-1 Monoclonal Antibody in the Treatment of ATC","Clinical Exploratory Study of NKG2D CAR-NK Combined with PD-1 Monoclonal Antibody in the Treatment of Anaplastic Thyroid Cancer (ATC)","Inclusion Criteria:\n\n1. Age 18-75 years (including boundary values), male or female.\n2. Be diagnosed with anaplastic thyroid cancer histopathologically with a measurable lesion≥1cm.\n3. Liver and kidney function is good, and can tolerate treatment.\n4. Be able to cooperate with the completion of treatment and follow-up work.\n5. No other systemic diseases, including other malignancies.\n\nExclusion Criteria:\n\n1. Need to breastfeed the baby or have fertility needs；\n2. Immune system diseases;\n3. Diseases of the blood system;\n4. Mental system diseases;\n5. Interstitial pneumonia, lung disease, etc.;\n6. Failure to follow rules of this study.","ALL","18 Years","75 Years",{"count":63,"type":64},30,"ESTIMATED","INTERVENTIONAL",[67,68],"PHASE1","PHASE2","The patients with anaplastic thyroid cancer were treated with CAR-NK immune cells combined with PD-1 monoclonal antibody, and the safety and tolerability of the patients were observed and evaluated.",[71],"Anaplastic Throid Carcinoma","NOT_YET_RECRUITING","2025-02-26",{"date":75,"type":76},"2025-03-04","ACTUAL",{"date":78,"type":64},"2025-02-22",{"date":80,"type":64},"2029-03-01",{"name":5,"class":6},1]